Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Keloid fibroblasts are specialized connective tissue cells found in keloid scars, characterized by uncontrolled proliferation and excessive secretion of extracellular matrix components, especially type I and III collagen, in response to wound healing signals. Their abnormal function is driven by heightened sensitivity to profibrotic cytokines, primarily TGF-β, and altered expression of cell surface receptors and proteases like FAP. These cells are central to the pathogenesis of keloid disorder, which is a model of skin fibrosis[1][2][3][4][5][6]. Keloid fibroblast secretion function therefore describes a pathological process, not a pharmacological target or singular molecular entity.
Inhibition of growth factor signaling (e.g., anti-TGF-β)[2][3]; Inhibition of ECM synthesis; Induction of fibroblast apoptosis or senescence
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Keloid fibroblast.